about
hCDC4 gene mutations in endometrial cancerCorrelation of an epigenetic mitotic clock with cancer riskRole of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer developmentGenome-scale screen for DNA methylation-based detection markers for ovarian cancerA randomised controlled trial comparing surgical intervention rates between two protocols for the management of asymptomatic adnexal tumours in postmenopausal womenOvarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.A systems-level integrative framework for genome-wide DNA methylation and gene expression data identifies differential gene expression modules under epigenetic control.Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle studyHypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.Development and validation of a method for profiling post-translational modification activities using protein microarrays.Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer.PP2A-B55β antagonizes cyclin E1 proteolysis and promotes its dysregulation in cancer.Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.The dynamics of DNA methylation covariation patterns in carcinogenesis.New insights into p53 regulation and gene therapy for cancer.A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform.Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer.A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier StateCks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints.Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancerDNA methylation and breast carcinogenesis.Corruption of the intra-gene DNA methylation architecture is a hallmark of cancerToll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumorsElevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patientsRisk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent.An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancerAssociation of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal womenStochastic epigenetic outliers can define field defects in cancer.Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening.Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantationHigh serum levels of soluble CD44 variant isoform v5 are associated with favourable clinical outcome in ovarian cancer.Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges.Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records.Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution.Distinctive topology of age-associated epigenetic drift in the human interactomeThe multi-omic landscape of transcription factor inactivation in cancer.Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study.The lncRNA HOTAIR impacts on mesenchymal stem cells via triple helix formation.
P50
Q28218344-9A57CA9D-EF43-4F43-B4F1-09E5BB16F85BQ28390569-11D35552-E8C2-4AA6-AF28-677B67830551Q28509811-03D8AC7A-6F17-4D92-A015-E66D3C768A1AQ28741759-68888BE7-834A-49BF-9F4A-2AE4AE05B319Q30459345-8802D942-C9A8-4416-8A64-26C49B44BF3CQ30724410-81EF738D-7F37-43DD-AFED-EC23AED1FF0EQ30814081-E138AA34-4C1D-4F4B-A511-7154E1A65A3CQ33352027-9C4C0F99-1D73-4B37-9D97-80E6C6018775Q33572253-8BCD30F6-14AF-40D8-9C41-BCEA25614DE0Q33623702-957E5199-ECAB-4913-8E42-DC3A54DF896CQ33762434-CB065379-C007-4273-BDE3-C588EB3D9D94Q33782728-E0195ACA-6347-4466-B9EF-8198512B17E8Q33827681-1A74BAE2-CDFD-4043-890F-0962B3FAE9B6Q33880743-90EA59AA-212D-48BE-B9D4-BAC58A8D418EQ34047246-7A02BE0B-370A-44B6-8369-21882304194DQ34242041-086333A7-CF36-43BF-AE1F-7D4E2290F51DQ34334842-8CBFD25F-A613-49C7-B7B3-3847C1D1BE0AQ34503833-4DDD8283-A224-44D6-A3D0-2DBEDF0F5437Q34577252-6C10371C-D27B-4BEA-B921-33783D4A7441Q34613635-D8C3D7E5-7FBD-4B26-8E77-827293278FFCQ34770599-0DCD7027-F5EC-4473-89DC-6013EED2B686Q34847813-D648B102-3D4E-4C6E-9285-C73A75DD2B13Q35286762-5FB13A5F-6CDF-46A1-A8BE-8C562DFC717CQ35653787-ACBD8AB9-EB26-41E0-BA91-13965FAD61E3Q35721991-2D943BCB-0BA9-4081-BD4F-247EDB5BFB75Q35815854-564571BF-AFD2-48CE-B114-5C7749C04036Q35848254-4D158480-94D7-40A4-8BD9-FD2B99FBD7EBQ35878943-FE635A8F-4C3C-471D-B2F9-92651261E726Q35996599-2C08512D-C49A-4CBD-A547-0B18C4C8EE53Q36072762-7C73245B-B2D0-4E30-B332-6D5A74560202Q36252676-92416F11-677B-4605-99D5-3D797C0C8FA5Q36376817-197FA957-07D5-479D-91E4-385EECEB8089Q36431610-66DB15E0-DD49-403B-954A-E32706AA29C7Q36763159-238B1964-980E-4228-BB05-F0D510907834Q36866311-DB271933-72E3-4780-90B4-88506A23D3BAQ36959885-BA307F90-4BC8-45EA-87F7-A8080CFDB600Q37143466-BDC01453-9AD5-42D2-903C-264ECC0BB46DQ37203595-1DF8357A-59D1-4B4A-B59C-8BDBFF830EBBQ37269668-88E8F626-87DE-4CD3-837D-65BD868D99A3Q37507597-9D4836CF-9630-41FF-9370-80466719908C
P50
description
researcher
@en
wetenschapper
@nl
name
M Widschwendter
@en
M Widschwendter
@nl
type
label
M Widschwendter
@en
M Widschwendter
@nl
prefLabel
M Widschwendter
@en
M Widschwendter
@nl
P106
P31
P496
0000-0002-7778-8380